The FDA has accepted a New Drug Application for silodosin, a novel alpha1-adrenoreceptor antagonist, from Watson Pharmaceuticals, Inc., of Corona, Calif. Watson is seeking approval of silodosin for the treatment of BPH symptoms.

Irritative lower urinary tract symptoms (LUTS) and nocturia are positively associated with diabetes, a study found. The relationship is greater in black than white men.

BP surges occur in many men undergoing transurethral microwave therapy (TUMT) for BPH, according to researchers at the Mayo Clinic in Rochester, Minn.

The efficacy of holmium laser enucleation of the prostate (HoLEP) in the treatment of symptomatic BPH increases with prostate size, according to researchers in India.

A diet high in vegetable intake is associated with a lower risk of surgically treated BPH, according to Australian researchers.

PHYSICAL ACTIVITY reduces the risk of BPH and lower urinary tract symptoms (LUTS), according to a review of studies that included a total of 43,083 men.

Using an assay they developed to detect antibodies to Propionibacterium acnes bacteria, researchers have found a link between these bacteria and development of inflammation-related prostate diseases.

PARIS—Ozarelix, an investigational agent, may be effective for selected men with lower urinary tract symptoms (LUTS) associated with BPH, phase II trial data suggest. The drug is a highly soluble luteinizing hormone releasing antagonist.

PARIS—Men with lower urinary tract symptoms (LUTS) associated with BPH may benefit more from a combination of tolterodine extended-release and tamsulosin than from either medication alone.

PARIS—Dutasteride is more effective than tamsulosin for treating men with moderate-to-severe urinary symptoms of BPH, data suggest.